Human CD44 standard isoform cDNA (hCD44s) was transfected into sis-transformed Balb/c 3T3 cells and into ras-revertant IIIA4 cells (both tumorigenic but nonmetastatic). Transfectants were injected subcutaneously into athymic nude mice to elucidate the functional role of hCD44s over-expression in progression and metastasis. The transfectants (but not parental cells) were capable of lung micrometastasis and of binding exogenously-added hyaluronan. hCD44s protein expression was conserved in lung micrometastases suggesting that it may have been necessary for their formation. In contrast, no hCD44s protein was detected in large subcutaneous (s.c.) tumors but normal levels of murine CD44 were detected. A second round of tumor development, using these two tumor cell classes, demonstrated that hCD44s-nonexpressing s.c. tumor cells re-expressed it in lung micrometastases. Conversely, hCD44s-expressing lung micrometastatic cells, when injected into a second group of mice, downregulated hCD44s expression in order to grow sizable s.c. tumors. S.c. tumor cells still contained the hCD44s gene but its expression was inhibited by epigenetic mechanisms, one of which was shown to be methylation of the hCD44s gene. These studies demonstrate (a) opposing selective pressures on CD44s over-expression for s.c. tumor growth and for metastatic spread to the lung and (b) further credence for the signi®cance of CD44 for metastatic spread of ®brosarcomas. Therefore, CD44s may be a critical component of the metastatic phenotype induced by speci®c oncogenes.
Introduction
CD44 is a cell surface receptor for the large extracellular matrix glycosaminoglycan hyaluronan. It is a heterogeneous family of cell surface glycoproteins and a`part-time' proteoglycan, the heterogeneity of which is generated by alternative splicing of ten variable exons (Lesley et al., 1993) . A variant CD44 (CD44v) can induce spontaneous metastatis of a rat pancreatic carcinoma (Gunthert et al., 1991) while standard CD44 isoform (i.e., CD44s lacking alternatively spliced sequences) induces experimental metastatis of a human B-cell lymphoma (Sy et al., 1991) .
Initial PCR-based studies of variant CD44 expression in human clinical tumor samples yielded correlative results Wielenga et al., 1993) . Studies with monoclonal antibodies against variable exons of CD44, however, have produced variable results. Some colorectal carcinomas demonstrate positive correlation between CD44v expression and tumor progression (Sinn et al., 1995) while others lack any correlation (Fox et al., 1994) or an inverse correlation (Jackson et al., 1995) . Thus CD44 may be a marker for metastasis of some types of tumors but not for others (Lewin, 1996) .
Our previous studies reported a correlation in a mouse ®brosarcoma model between CD44 standard isoform expression and metastasis (Kogerman et al., 1996a (Kogerman et al., ,b, 1997 . This model utilizes murine Balb/c 3T3 cells transformed with dierent oncogenes. This current study was therefore undertaken to test the functional importance of CD44 standard isoform in tumor metastasis more directly by regulating the amounts of CD44 being expressed via transfection of the cDNA for human CD44s. Our results demonstrate for the ®rst time the induction of spontaneous metastasis by overexpressed CD44 standard isoform in normally tumorigenic but not metastatic cells. In contrast, loss of expression of the transfected human CD44 gene during subcutaneous tumor development suggests that CD44 is irrelevant or disadvantageous for primary tumor growth.
Results

Transfected human CD44s gene is expressed and functional in mouse cells
Human CD44 standard isoform cDNA (Stamenkovic et al., 1989) was transfected into c-sis transformed HUSI cells (a Balb/c 3T3 derivative) to create hCD44s-overexpressing variants. hCD44s-expressing clones were isolated by¯uorescence-activated cell sorting using two dierent human CD44-speci®c monoclonal antibodies. These antibodies (GKWA3 and 7.10 ± Guo et al., 1993 Guo et al., , 1994 do not react with nontransfected or mock-transfected 3T3 mouse cells (data not shown). As shown in Figure 1 (panels a and b), two independent CD44 transfectants (hCD44.5 and hCD44.6) express hCD44s on their cell surfaces in addition to murine CD44. One of the best-characterized ligands for CD44 is hyaluronan acid (HA). Binding of CD44 to HA is a complex, dynamic process. Despite the expression of signi®cant levels of murine CD44 on parental HUSI cells, they do not bind any detectable levels of FITC-HA (Kogerman et al., 1996b) . In contrast, transfectants bearing hCD44s bind high levels of FITC-HA ( Figure 1c ). Binding of FITC-HA to transfectants is dependent on human CD44 as shown by blocking of binding with monoclonal antibody speci®c for human CD44. Interestingly, binding of FITC-HA to hCD44s transfectants can also be partially blocked with monoclonal antibody speci®c for murine CD44 (data not shown). Cells may need to express higher levels of murine or human CD44 to allow for binding of FITC-HA; alternatively, there may be qualitative dierences in these two CD44 classes in their association with neighboring molecules.
Induction of lung metastasis in murine ®brosarcoma cells by over-expression of hCD44s
The tumorigenicity and metastatic capacity of CD44 transfectants were tested next in athymic nude mice. Parental HUSI cells or CD44 transfectants were injected subcutaneously (s.c.) into athymic nude mice and tumor growth monitored with time. As shown in Table 1 , the transfectants gave tumors that were slightly slower-growing and with a longer latency than the parental cells. Due to intrinsic variability in these types of tumor analyses, these dierences were only marginally signi®cant when analysed statistically (P=0.04 for latency and P=0.1 for doubling time by two-tailed, two-sample (unequal variance, heteroscedastic) t-test).
By gross examination, no overt metastases were detected in the lung, liver, spleen, kidney, pancreas or gastrointestinal tract of the tumor-bearing animals. To investigate whether micrometastatic tumor cells can be recovered from tumor-bearing animals, these organs, as well as s.c. tumors, were dispersed into culture in the presence of hygromycin. No drug-resistant tumor cells were isolated from any organs of the mice injected with parental HUSI cells using this procedure, even though tumor cells could be easily isolated from the s.c. tumors (Table 1 ). In contrast, 3/3 animals injected with hCD44s transfectants yielded tumor cells from the lungs (but not from any other organs) as early as two months post-injection. These cells were resistant to selectable markers hygromycin and puromycin (data not shown), indicating their derivation from the subcutaneously-injected tumor cell population. Since no gross metastases could be detected in the lungs, these tumors must be derived from micrometastases.
To con®rm these results in a dierent system, we chose IIIA4 cells, a¯at Ki-ras negative revertant variant of reduced tumorigenic capacity isolated from Ki-rastransformed Balb/c 3T3 cells (Radinsky et al., 1991) . We previously demonstrated that CD44 expression and binding to its ligand hyaluronan are reduced in these revertant cells relative to Ki-ras transformants (Kogerman et al., 1996b) . These properties correlate with reversion to the nonmetastatic phenotype: Ki-rastransformed cells are metastatic to the lung (Radinsky et al., 1987) , whereas no lung metastases was seen in any of the ®ve animals injected with IIIA4 cells (Table 2 ). : Three tumor-bearing animals from each group were analyzed for the presence of micrometastatic cells hCD44s-overexpressing IIIA4 variants were created using the same transfection protocol as for HUSI cells. Two independent isolates (clones 1 and 6) were injected s.c. into nude mice. As shown in Table 2 , tumor incidence at the s.c. site was reduced in both of these clones. The s.c. tumors developing from injection of hCD44s transfectants had both increased latency and doubling time when compared to tumors from parental IIIA4 cells (P50.0001 and P50.01, respectively). Again, lung metastasis was observed in both of these clones by hCD44s over-expression (Table 2 ) while no parental IIIA4 cells could be obtained from the lungs. Signi®cant clone-speci®c dierences were observed with metastasis to other organs: one clone was metastatic while the other was nonmetastatic (Table 2 ). These data demonstrate induction of lung metastasis by hCD44s over-expression in four independent clones generated from two dierent murine cell lines. In contrast, hCD44s over-expression was inhibitory (or selected against) in s.c. tumors.
Dierential expression of hCD44s in s.c. tumor versus lung micrometastatic cells Tumor allografts from s.c. tumors and lung micrometastases were analysed for their cell surface CD44 . This result was true for 15 independent s.c. tumors analysed and was also con®rmed by immunohistochemical staining of tumor sections with hCD44-speci®c antibody GKWA3 (P Kogerman and LA Culp, Clin. Exp. Metastasis, in press, 1977) . In contrast, these s.c. tumor cell populations express normal levels of murine CD44. We cannot rule out the possibility that these tumors may have a low level of hCD44s protein that is not detectable by FACS at the cell surface. Alternatively, hCD44s may be expressed by only a very small subset of s.c. tumor cells that again would not be resolved by FACS analysis.
In contrast to s.c. tumors, tumor cells isolated from the lung contained readily detectable levels of both human and mouse CD44 proteins (Figure 2b and d). This was true for many dierent lungs analysed (n=6). Similar results were obtained with tumor allografts from hCD44s-overexpressing IIIA4 cells (Table 2) . These data provide further evidence that hCD44s-expressing cells are selected against during s.c. tumor growth and selected for during metastatic spread to the lung.
hCD44s-transfected tumor cells`breed true' in secondround tumors
To further investigate inverse relationship between hCD44s protein levels in these two tumor classes, a second round of tumor development was performed with each population. hCD44s 7 cell lines were developed from s.c. tumors from mice injected previously with hCD44s + transfectants of HUSI cells. One of these tumor cell lines (5.2) was reinjected subcutaneously into new animals. As shown in Table 3 , both tumor latency and doubling time were decreased signi®cantly in second-round tumors when compared to ®rst-round as expected (P50.0001 and P50.01, respectively). The s.c. tumor cells were also negative for the hCD44s protein ( Figure 3 ). Tumor cells were easily isolated from the lungs of these second-round animals and of particular note these lung metastatic populations re-expressed hCD44s protein on their cell surfaces (Figure 3) , demonstrating again the signi®cance of the overexpression of the human gene for metastatic spread.
Lung metastatic populations (hCD44s + ) from ®rst-round tumors were also analysed by a second round of tumorigenesis in nude mice. These populations were isolated from the lungs of a mouse injected earlier with hCD44s + transfectants. One population (6.5(+) cells, hCD44s + ) gave rise to s.c. tumors at 4/6 injected sites (Table 3 ). In this case also, the tumors displayed signi®cantly shorter doubling times than the ®rst-round tumors (P<0.005); tumor latency, on the other hand, was not signi®cantly changed (Table 3) . These s.c. tumors were also hCD44s 7 when analysed by FACS (Figure 4a ). Similar to earlier observations, lung micrometastatic cells were hCD44s + ( Figure 4b ). With these cells, 2/3 mice also had metastases to other organs (kidney and G.I. tract); these metastases were shown to be hCD44s
7 by FACS analysis (Figure 4c and d), suggesting that selection for hCD44s expression may be lung-speci®c.
We also tested the tumorigenic and metastatic capacity of a lung metastatic cell population in nude mice after it had lost hCD44s expression in culture (6.5(7) cells). These cells generated s.c. tumors with ± by FACS analysis Figure 3 Human CD44s-negative s.c. tumor cells give rise upon reinjection to hCD44s-negative s.c. tumors and hCD44-positive lung micrometastases. Second-round tumorigenesis with cells isolated from a s.c. tumor using hCD44s transfectant 5, isolation of s.c. tumor and lung micrometastatic cells, and FACS were performed as described in Materials and methods. 7.10 -hCD44-speci®c anti-CD44 antibody shorter latency (Table 3 ) than 6.5(+) cells, suggesting that the latter had to lose hCD44s expression before the tumors could grow to detectable sizes. These injections also yielded hCD44s + tumor cells in the lungs (Table 3) .
Human CD44s gene is present in both s.c. tumors and lung micrometastases but only lung populations contain hCD44s mRNA
Tumor cells may lose cell surface hCD44s protein by deleting/rearranging the transfected gene, by inhibiting the transcription or translation of the hCD44s gene, or alternatively by shedding of hCD44s protein from the cell surface. To dissect the mechanism(s) of loss of hCD44s protein in s.c. tumors, Southern blot analyses were performed with XhoI-digested genomic DNAs isolated from parental cells, transfectants and tumor cell populations with a probe complementary to the hCD44s sequence. XhoI is a rare-cutting restriction enzyme ± fragments containing the endogenous mouse CD44 gene are so large that they do not migrate into the gel (data not shown). The hCD44s-expressing plasmid, however, contains two XhoI sites and yields a restriction fragment of 2 kb containing the hCD44s sequence. As shown in Figure 5 , no hCD44s is detected in parental HUSI cells as expected (lane 1) but hCD44s can be detected in the transfectant (lane 2 for clone 6). Human CD44s gene is also present in two dierent s.c. tumors generated by injection of transfectant 6 (lanes 3 and 4), as well as in their metastases to the lung or gastrointestinal tract (lanes 5 and 6, respectively). Please note that no hCD44s protein can be detected in s.c. tumors or gastrointestinal metastases. Similar results were obtained also with HUSI hCD44s transfectant ®ve and IIIA4 transfectant one (data not shown). Two independent s.c. tumors arising from injection of IIIA4 hCD44s transfectant 6, however, contained no hCD44s-speci®c XhoI fragment, indicating that in this case hCD44 gene had been deleted (data not shown). These results demonstrate that, in most cases, the transfected hCD44s gene is retained by To further analyse the mechanism of loss of hCD44s protein in tumor cells containing the hCD44s gene, the presence of human CD44s mRNA was investigated with the Ribonuclease Protection Assay with a probe complementary to the divergent 3' untranslated region of hCD44s mRNA. This probe also contains 50 bases of coding region of the highly conserved CD44 cytoplasmic domain that protects the respective region in the mouse CD44 mRNAs. As shown in Figure 6 , a hCD44s transfectant (lane 2) but not parental cells (lane 1) express hCD44s mRNA. No hCD44s mRNA can be detected in s.c. tumor cells (lanes 3 and 4) . However, human CD44s mRNA is apparent in lung micrometastatic cells (lane 5). Mouse CD44 mRNA can be detected in all of these cells as a 50-nucleotide protected fragment. These results suggest that in s.c. tumors hCD44s expression is prevented at the level of transcription.
Expression of hCD44s gene is inhibited by its methylation in s.c. tumor cells
Methylation has been identi®ed as one mechanism by which tumor cells shut down the expression of suppressor genes such as p16 (Merlo et al., 1995) and other gene classes (Gorzowski et al., 1995) . To test whether the hCD44s gene was methylated in s.c. tumors selectively, Southern blot analysis was performed using the methylation-sensitive restriction enzyme HhaI. As shown in Figure 7 , a large (ca. 25 kb) HbaI fragment of CD44 appears in all cell extracts. This band represents two gene sources ± a fragment from the endogenous mouse CD44 gene and a fragment from the methylated form of hCD44s gene. When the intensity of this band is compared and quantitated with an internal reference standard (the were grown in the presence of 3 mM 5-aza-2-deoxycytidine, a cytidine analog that cannot be methylated and has thus been used to study the eects of methylation/demethylation on gene expression (Gorzowski et al., 1995; Merlo et al., 1995) . After four days of cell growth + the nucleoside analog, the cells were harvested and their hCD44s expression was analysed by FACS. As shown in Table  4 , this treatment did not result in any hCD44s expression in parental HUSI cells as expected. In contrast, hCD44s protein became detectable in two s.c. tumor cell lines after treatment with the analogue (Table 4) . Interestingly, hCD44s expression was also enhanced somewhat by aza-deoxycytidine treatment of parental transfectants and their lung metastatic cell counterparts, which already express hCD44s protein (Table 4) . Treatment of three of these cell lines with 0.75 or 1.5 mM aza-deoxycytidine established that this enhancement/induction occurs in a dose-dependent manner (data not shown). These results suggest further that DNA methylation plays some role in hCD44s transcriptional silencing in s.c. tumor cell populations.
Discussion
This study demonstrates for the ®rst time the induction of spontaneous metastasis by over-expressed hCD44 standard isoform in two distinct nonmetastatic ®brosarcoma cell populations (sis-transformed 3T3 cells and a revertant variant of ras-transformed 3T3 cells). This occurs in a background of normal levels of mouse CD44, indicating that the amounts and/or qualitative nature of human CD44s protein at the cell surface are conveying this competence. This contrasts with counter-selection against hCD44s-over-expressing cells in sizable subcutaneous tumors, a down-regulation that may occur by an epigenetic mechanism involving dierential methylation.
Sy and coworkers showed enhanced metastasis and tumorigenicity induced by expression of CD44 standard isoform in an experimental metastasis assay of a B-cell lymphoma (Sy et al., 1991) . In contrast, the standard isoform was inactive in a spontaneous metastasis assay in a rat pancreatic carcinoma model system (Gunthert et al., 1991; Rudy et al., 1993 ). Our results demonstrate induction of lung micrometastasis by over-expressed hCD44s in a spontaneous metastasis assay and in two dierent ®brosarcomas. These studies together indicate that CD44's utility for tumor progression is tumor type-speci®c and possibly very dependent on the amounts of CD44 at the cell surface and/or its state of association with other cell surface molecules. Another explanation for these results is that over-expression of CD44 standard isoform inhibits s.c. and secondary tumor growth beyond a certain minimal size whereas the variant isoform does not have this activity. Finally, it is possible that local organ microenvironments regulate hCD44s dierently as demonstrated for other gene classes (Fidler et al., 1994; Radinsky et al., 1992) . This possibility is particularly interesting since it would involve novel dierential regulation of DNA methylation by organ microenvironments. Other approaches will be required to resolve these possibilities.
These results demonstrate that elevated levels of hCD44s can suppress s.c. tumor growth and that this suppression is overcome in s.c. tumors via downregulation of this gene's transcription. These tumors still express endogenous mouse CD44. There must be a qualitative dierence between these two proteins at the cell surface so that one but not the other promotes downregulation in order to optimize s.c. tumor growth. Human CD44s expression also induced much more eective binding to HA. It may be this qualitative change that is particularly important for inducing micrometastasis to the lung as well as for inhibition of s.c. tumor growth. These possibilities will be directly tested in future experiments by transfecting a`tagged' murine CD44s gene, as well as HA-nonbinding mutants, into the same cell types.
Under shear stress, CD44 and HA binding mediate rolling and adhesion of leukocytes on an endothelial model (DeGrendele et al., 1996) . Therefore, CD44 and HA could similarly mediate adhesion of tumor cells to the lung capillary endothelium. HA fragments have been previously shown to induce tumor angiogenesis, whereas high molecular weight hyaluronan inhibits this process (West et al., 1985) . CD44-over-expressing tumor cells may immobilize HA in the form of a protease-resistant HA coat on their surface that inhibits the migration of endothelial cells into the s.c. tumor. Alternatively, since CD44 has been implicated Cells were grown either normally or treated with 3 mM 5-azadeoxycytidine (aza-cyt) for 3 ± 4 days and their hCD44s levels were analysed by FACS as described in Materials and methods and legend to Figure 1 . The results were quantitated using the LYSYS software (Becton-Dickinson); mean¯uorescent intensities of cell populations stained with irrelevant antibody (BG) or hCD44-speci®c antibody (hCD44s) are shown. *: Not signi®cantly dierent from background (BG) in uptake of HA and its targeting to intracellular degradation (Culty et al., 1992 (Culty et al., , 1994 , hCD44s expression in s.c. tumor cells may deplete the extracellular matrix of angiogenic HA fragments, resulting in net inhibition of angiogenesis. Another possibility is that the dierential eects of transfected hCD44s and mouse endogenous CD44 genes on tumor growth may be caused by dierent post-translational modi®cations and/or very dierent qualitative association with neighboring cell surface molecules. This study has also shown functional involvement of hCD44s in tumor metastasis in two ®brosarcoma animal models. This stands in contrast to the variable expression of hCD44 isoforms in human clinical specimens (Lewin, 1996) . One possible explanation for these results may be dierent mechanisms of tumor metastasis in humans and in animal models. Most animal model systems are ectopic and not orthotopic (i.e. the injection route does not accurately mimick the natural progression of the human cancer counterpart). Another explanation may lie in the very dierent gene expression programs that are necessary for tumor growth at dierent sites and for the complex processes of tumor dissemination. It has been suggested that molecules necessary for metastasis may be irrelevant or even disadvantageous for s.c. and secondary tumor growth and downregulated during these processes (Nicolson, 1993) . Our results suggest that CD44 may be an example of such a type of metastasis-promoting (but s.c. tumor-inhibiting) molecule.
How does hCD44s expedite micrometastasis from a primary tumor site where its expression is being aggressively downregulated? There are two possibilities to consider in this regard. (a) hCD44s + cells may migrate to the lungs very early in s.c. tumor development when they are still hCD44s-positive. Or (b) hCD44s could be expressed in a very small fraction of s.c. tumor cells that cannot be detected by the analytical methods used herein. This small fraction may be sucient to initiate successful micrometastatic spread to the lung since it has been proposed that the metastatic phenotype is expressed by a minority of tumor cells at any given time (Weiss, 1990) . In conclusion, the data presented in this study demonstrate a novel type of counter-selection for the metastasis-associated molecule CD44 during tumor progression and may have wider implications for the study of tumor progression and metastasis in many malignancies.
Materials and methods
Cell culture
All cells were maintained Mycoplasma-free in Dulbecco's Modi®ed Eagle's Medium containing antibiotics and 10% newborn calf serum (GIBCO BRL, Grand Island, NY). Cells were rinsed three times with phosphate-buered saline (PBS) and detached with either 5 mM EDTA in PBS at 378C with shaking (for FACS analysis) or with 0.5% (w/v) trypsin/0.05 mM EDTA in PBS (for all other experiments).
Isolation of hCD44s transfectants
Human CD44 standard isoform cDNA (Stamenkovic et al., 1989) was subcloned into the prc/RSV eukaryotic expression plasmid (Invitrogen) to utilize the RSV LTR promoter. The plasmid was introduced into c-sis-transformed Balb/c 3T3 cells (HUSI; KL O'Connor and LA Culp, unpublished data) or ras-revertant IIIA4 cells (Radinsky et al., 1991) by cotransfection with the pBABE-puro plasmid, harboring the puromycin R gene (from Dr D Templeton of this University), using the standard calcium phosphate precipitation procedure (Sambrook et al., 1989) . After selection in 5 mg/ml puromycin, resistant colonies were picked, expanded and analysed for hCD44s expression by¯uorescence-activated cell sorting (FACS) with the mouse anti-human CD44 monoclonal antibody A3D8 (Sigma Chemical Company, St Louis, MO). This antibody does not crossreact with mouse CD44. Stable transfection eciency ranged from 0.01 ± 0.03%. Two positive isolates from independent transfections of HUSI (HUSI.hCD44.5 and HUSI.hCD44.6) and IIIA4 (IIA4.hCD44.1 and IIIA4.hCD44.6) were selected for analysis herein.
Tumor formation in nude mice
Female athymic nude mice (HSD nu/nu) were maintained in the Case Western Reserve University Cancer Center (AAALAC-accredited Athymic Animal Facility). Protocols were approved by the Case Western Reserve University Animal Care and Use Committee. Tumor cells were detached from culture plates as described above and resuspended at a concentration of 10 6 cells/ml; 0.1 ml of cell suspension was injected bilaterally into the subcutaneous space of the back of 6 ± 8-week-old animals. Animals were monitored twice a week for tumor formation. Tumor latency was determined as time required for tumors to reach 3 mm in diameter. Tumor volumes were obtained by measuring two surface dimensions of the tumors and calculation with the National Cancer Institute formula (volume (mm 3 )=1 * w 2 ;17the long dimension (mm); w7the short dimension (mm) of the tumor (Houchens et al., 1978) . Statistical analysis of the data was performed with Microsoft Excel using a two-tailed heteroscedastic t-test.
Tumors were allowed to grow to 10 ± 20 mm in diameter; the tumor-bearing mice were euthanized. The tumors , lungs and other tissues including liver, kidney, pancreas, spleen and the gastrointestinal tract were examined with a Nikon SMZU dissecting microscope and either snap-frozen for further analysis or dispersed into culture by incubation with trypsin/EDTA for 30 min at 378C. The dispersed organs were incubated on tissue culture plates in DMEM containing 10% NCS. The next day the media, debri and unattached cells were discarded and fresh media added to the attached cells. The s.c. tumor allografts obtained this way grew to approximately 70 ± 80% con¯uence and were analysed by FACS for CD44 levels. Cells were also expanded for RNA/ DNA analyses, establishment of frozen cell stock and selection experiments with selective markers hygromycin and puromycin to con®rm their derivation from the originally-injected cells.
Fluorescence-activated cell sorting (FACS)
FACS was performed essentially as described before (Kogerman et al., 1996b) . Brie¯y, cells were detached from tissue culture plates by EDTA treatment, centrifuged and resuspended in Stain Wash Media (SWM, 0.5% (w/v) bovine serum albumin, 0.01% sodium azide in PBS). 1 ± 5610 5 cells were used for each staining reaction to which 50 ml appropriate hybridoma supernatant or 1 mg of puri®ed antibody was added. Hybridomas include KM81 producing rat anti-mouse CD44 (no crossreaction to human CD44 (Miyake et al., 1990) ) or from GKWA3 or 7.10 hybridomas producing mouse anti-human CD44 (Guo et al., 1993 (Guo et al., , 1994 ; no cross-reaction to mouse CD44).
Puri®ed A3D8 mouse anti-human CD44 was purchased from the Sigma Chemical Company (St. Louis, MO). After 1 hr incubation on ice, cells were washed in SWM and appropriate FITC-conjugated secondary antibodies (from Jackson Immunoresearch, West Grove, PA) were added to the cells for 30 min. Following washes, the¯uorescence of the cells was determined on a Becton-Dickinson FACScan Flow Cytometer and the data were analysed using the LYSYS software (Becton-Dickinson). For a negative control, cells were incubated with an irrelevant hybridoma supernatant (anti-K k D k MHC-I). For FITC-HA-binding experiments, FITC-conjugated high molecular weight hyaluronan (Guo et al., 1993) was incubated with the cells for 1 hr followed by washes in SWM. The controls for these experiments included preincubation of cells with unconjugated HA or anti-CD44 monoclonal antibodies.
RNA isolation and RNAse protection assay
The s.c. tumors were lyophilized overnight and homogenized. Tissue culture cells were detached from the plates by trypsinization and collected by centrifugation. The total cellular RNAs were extracted and puri®ed using RNAzol reagent (BiotecX Laboratories, Inc., Houston, TX) according to manufacturer's instructions.
The human CD44s cDNA was subcloned into pBS SK + plasmid (Stratagene), cut with PvuII restriction enzyme, and puri®ed by standard phenol/chloroform extraction followed by ethanol precipitation (Sambrook et al., 1989) . The human CD44s antisense probe was transcribed from this template using an in vitro transcription kit from Promega (Madison, WI) with the T3 RNA polymerase and [a 32 P]-UTP (DuPont/ NEN; Boston, MA) as the radiolabelling nucleotide. The fulllength probe was gel-puri®ed. This probe is complementary to a 194 base region in the mRNA, 50 bases of which is coding sequence and the remainder is 3'-untranslated region. Due to the high degree of conservation of the C-terminus of CD44 between species, the mouse CD44 mRNA also protects a 50-base region of the probe. A control probe was generated with the Megascript Transcription kit (Ambion) using pT718S carrying a partial cDNA to ribosomal 18S rRNA as a template.
RNAse protection assays were done with Ambion's RPA I kit according to manufacturer's instructions. Ten mg of the RNAs were denatured and hybridized overnight with at least 10-fold excess of CD44 probe plus at least fourfold excess of the control probe. Samples were digested with an RNAse A/ T1 mix; the RNAs were then puri®ed and separated on a 6% denaturing polyacrylamide gel. The gels were ®xed, dried and exposed to X-ray ®lms. The positive controls were 1% (in case of CD44 probe) or 10% (for control probe) of the amount of the probes used in the RPA reaction that were treated identically, except when the RNAse in the reaction mixture was omitted. Negative controls included RNAse digestion of mock-hybridized probes and hybridization to RNAs from hCD44-negative parental cells.
Preparation of genomic DNAs and Southern blot analysis
For preparation of genomic DNAs, cultured cells were collected as described above. The s.c. tumors were thawed and cut into small pieces. The DNA puri®cation procedure has been described before (Radinsky et al., 1991) . Brie¯y, cells/tumors were lysed with SDS, digested extensively with proteinase K, extracted with phenol/chloroform, dialyzed, digested with RNAse A and ®nally extracted and dialyzed again. Twenty mg of each of the DNAs were digested with XhoI or the methylation-sensitive restriction enzyme HhaI, fragments separated by agarose electrophoresis, and transferred to Hybond nylon membranes (Amersham Life Sciences) by capillary transfer. The DNAs were ®xed to the membranes by baking in a vacuum oven for 2 h.
The radiolabeled probes were prepared with the random primer labeling kit (Boehringer Mannheim; Indianapolis, IN) using [a-32 P]-dCTP (DuPont/NEN, Boston, MA) resulting in probes with speci®c activities greater than 10 9 c.p.m./mg DNA. Probes were hybridized to membranes for 2 ± 3 h using Amersham's Rapid hybridization buer. After stringent washes (15 mM NaCl, 658C), membranes were exposed to Xray ®lms.
Azadeoxycytidine treatment of tumor cells
Tumor cells were treated with normal growth media containing 0, 0.75, 1.5, or 3 mM 5-aza-deoxycytidine (Fluka, Buchs, Switzerland) for 3 ± 4 days as described previously (Merlo et al., 1995) . Cells were harvested and their cell surface hCD44s levels analysed by FACS. As 3 mM was optimal for hCD44 induction, only this concentration along with the negative control was used in later experiments.
